Zacks Investment Research on MSN1d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
MedTech Dive1d
Dexcom rejects claims of unauthorized device changes in FDA warning letter
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
Medscape4d
Dexcom’s 15-day CGM Adds Wear Time, Accuracy to Current G7
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
Drug Delivery Business7d
Why Dexcom is making a push to bring CGM to more people with type 2 diabetes
Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.
MedTech Dive19h
Newly public Beta Bionics reports sales surge; Dexcom hires CCO
Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...
Investopedia18d
DexCom Stock Drops as Diabetes Devices Maker Gets FDA Warning Letter
Cheng Xin / Getty Images DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants. The maker of glucose monitoring devices said ...
Drug Delivery Business9d
Dexcom CGM now connects with Novo Nordisk smart insulin pens, 15-day CGM shows promise
Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...